Cancer Targeted Technology news
The most recent performance data on Cancer Targeted Technology’s (CTT) leading drugs, CTT1057 and CTT1403, in prostate cancer clinical and preclinical studies will be presented at several scientific and business meetings in June and one that took place in April, the company announced in a press release.
The meetings featuring CTT presentations include the American Society of Clinical Oncologists (ASCO) 2017 Annual Meeting June 2-6 in Chicago; t
Cancer Targeted Technology (CTT) receives milestone payment for development of diagnostic PET imaging agent for prostate cancer. Seattle, Washington, June 2021. Cancer Targeted Technology (CTT), a privately held Seattle-based biotechnology company, received a milestone payment from Advanced Accelerator Applications International S.A. (AAA), a Novartis company, trigg
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial.
The clinical trial, conducted at Universit
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced today that it filed an Investigational New Drug Application (IND) with the FDA to move forward a radiotherapeutic drug, CTT1403, into human clinical trials for prostate cancer. CTT1403 is a peptidomimetic drug that targets Prostate Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and this expression increases as the cancer metastasizes and becomes hormone-resistant. Unl
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company focusing on small molecules that bind to pivotal enzyme cancer targets, announced that it received a Small Business Innovation Research (SBIR) grant to develop CTT1700, a unique prodrug targeted at men with prostate cancer that express Prostate Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and this expression increases as the cancer metastasizes and becomes hormone-resista
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm, is focusing on small molecules that target pivotal enzyme targets on cancer. CTT’s theranostic program is focused on the development of two drugs, CTT1057 and CTT1403, that respectively diagnose and treat prostate cancer based on targeting the biomarker, Prostate Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and this expression increases as the cancer metastasizes and becom
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA). PSMA is over
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on small molecules that target pivotal enzyme targets on cancer, announced that a Phase I clinical trial has commenced in men with high risk metastatic prostate cancer. In late August, the Food and Drug Administration cleared CTT’s first Investigational New Drug Application (IND) for a Positron Emission Tomography (PET) imaging agent, CTT1057, labeled with a two-hour half life radiolabel, fluori
Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, today announced that the NIH awarded a 2-year, $2M SBIR grant to CTT to develop a new agent that will help diagnose and monitor metastatic prostate cancer. CTT1057, a positron emission tomography (PET) imaging agent, discovered by Dr. Cliff Berkman, Professor of Chemistry at Washington State University and CTT Chief Scientific Officer, may be well-suited for ima